Literature DB >> 730406

Narcotic antagonist treatment: clinical experience with naltrexone.

D C Lewis, J Mayer, R G Hersch, R Black.   

Abstract

Narcotic antagonist (naltrexone) treatment experience with 22 opioid addicts over a 29-month period shows that the mean duration of receipt of naltrexone was 6.2 weeks, and 12 subjects (55%) continued in treatment after cessation of naltrexone for an average of 5.6 weeks. Analysis of physical and behavioral measured revealed no toxicity, indicating that naltrexone appears to be a safe drug. Clinical evaluation of the patients receiving naltrexone suggests that ingestion of naltrexone provides a degree of external control, reducing the preoccupation with heroin and releasing energy for the pursuit of other goals. Subject follow-up at an average of 45.3 weeks after cessation of naltrexone indicated that 11 (58%) were known to be abstinent, and 9 (47%) subjects were employed compared with 3 (16%) employed at the onset of treatment.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 730406     DOI: 10.3109/10826087809039316

Source DB:  PubMed          Journal:  Int J Addict        ISSN: 0020-773X


  3 in total

Review 1.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

2.  A randomized trial of oral naltrexone for treating opioid-dependent offenders.

Authors:  Donna M Coviello; James W Cornish; Kevin G Lynch; Arthur I Alterman; Charles P O'Brien
Journal:  Am J Addict       Date:  2010 Sep-Oct

Review 3.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.